CONTEXT: Seasonal variability in 25-hydroxyvitamin D [25(OH)D] and PTH levels in the general population has been associated with differences in bone turnover markers, bone density, and fracture risk. Seasonal variability in 25(OH)D and PTH levels has also been reported in primary hyperparathyroidism (PHPT). OBJECTIVE: Given the widespread use of vitamin D supplements, we sought to determine whether patients with PHPT still demonstrated seasonal variation in 25(OH)D levels. DESIGN AND SETTING: This cross-sectional study was conducted at a university medical center at a Northeastern U.S. latitude (New York, NY). PATIENTS: One hundred patients with PHPT participated in the study. OUTCOME MEASURES: We assessed vitamin D supplement use and seasonal variation in serum 25(OH)D. RESULTS: Patients had PHPT ([mean ± SD] calcium, 10.8 ± 1.0 mg/dL; PTH, 85 ± 48 pg/mL) with a mean 25(OH)D level of 29 ± 10 ng/mL. Although only one fifth of participants had vitamin D deficiency (19% < 20 ng/mL), more than half were either deficient or insufficient (54% < 30 ng/mL). Sun exposure varied by season, but there were no seasonal differences in levels of 25(OH)D, PTH, bone markers, or bone mineral density, or in the prevalence of 25(OH)D less than 20 or less than 30 ng/mL. Most of the participants (65%) took supplemental vitamin D (dose among users: mean, 1643 ± 1496 IU; median, 1000 IU daily), and supplement users had markedly better vitamin D status than nonusers (25(OH)D < 20 ng/mL: 8 vs 40%; P < .0001; < 30 ng/mL: 40 vs 80%; P = .0001; ≥ 30 ng/mL: 60 vs 20%; P = .0001). CONCLUSIONS: We found no evidence of seasonal variation in 25(OH)D levels or PHPT disease severity in the Northeastern United States. This change is likely due to widespread high vitamin D supplement intake, which has resulted in better vitamin D status among supplement users and can mask the effect of season on serum 25(OH)D levels.
CONTEXT: Seasonal variability in 25-hydroxyvitamin D [25(OH)D] and PTH levels in the general population has been associated with differences in bone turnover markers, bone density, and fracture risk. Seasonal variability in 25(OH)D and PTH levels has also been reported in primary hyperparathyroidism (PHPT). OBJECTIVE: Given the widespread use of vitamin D supplements, we sought to determine whether patients with PHPT still demonstrated seasonal variation in 25(OH)D levels. DESIGN AND SETTING: This cross-sectional study was conducted at a university medical center at a Northeastern U.S. latitude (New York, NY). PATIENTS: One hundred patients with PHPT participated in the study. OUTCOME MEASURES: We assessed vitamin D supplement use and seasonal variation in serum 25(OH)D. RESULTS:Patients had PHPT ([mean ± SD] calcium, 10.8 ± 1.0 mg/dL; PTH, 85 ± 48 pg/mL) with a mean 25(OH)D level of 29 ± 10 ng/mL. Although only one fifth of participants had vitamin D deficiency (19% < 20 ng/mL), more than half were either deficient or insufficient (54% < 30 ng/mL). Sun exposure varied by season, but there were no seasonal differences in levels of 25(OH)D, PTH, bone markers, or bone mineral density, or in the prevalence of 25(OH)D less than 20 or less than 30 ng/mL. Most of the participants (65%) took supplemental vitamin D (dose among users: mean, 1643 ± 1496 IU; median, 1000 IU daily), and supplement users had markedly better vitamin D status than nonusers (25(OH)D < 20 ng/mL: 8 vs 40%; P < .0001; < 30 ng/mL: 40 vs 80%; P = .0001; ≥ 30 ng/mL: 60 vs 20%; P = .0001). CONCLUSIONS: We found no evidence of seasonal variation in 25(OH)D levels or PHPT disease severity in the Northeastern United States. This change is likely due to widespread high vitamin D supplement intake, which has resulted in better vitamin D status among supplement users and can mask the effect of season on serum 25(OH)D levels.
Authors: Claudie Berger; Linda S Greene-Finestone; Lisa Langsetmo; Nancy Kreiger; Lawrence Joseph; Christopher S Kovacs; J Brent Richards; Nick Hidiroglou; Kurtis Sarafin; K Shawn Davison; Jonathan D Adachi; Jacques Brown; David A Hanley; Jerilynn C Prior; David Goltzman Journal: J Bone Miner Res Date: 2012-06 Impact factor: 6.741
Authors: Margaret Ashwell; Elaine M Stone; Heiko Stolte; Kevin D Cashman; Helen Macdonald; Susan Lanham-New; Sara Hiom; Ann Webb; David Fraser Journal: Br J Nutr Date: 2010-06-04 Impact factor: 3.718
Authors: M D Walker; E Cong; J A Lee; A Kepley; C Zhang; D J McMahon; J P Bilezikian; S J Silverberg Journal: Osteoporos Int Date: 2015-06-18 Impact factor: 4.507
Authors: Emily M Stein; David W Dempster; Julia Udesky; Hua Zhou; John P Bilezikian; Elizabeth Shane; Shonni J Silverberg Journal: Bone Date: 2010-10-13 Impact factor: 4.398
Authors: A L Darling; K H Hart; M A Gibbs; F Gossiel; T Kantermann; K Horton; S Johnsen; J L Berry; D J Skene; R Eastell; R Vieth; S A Lanham-New Journal: Osteoporos Int Date: 2013-08-28 Impact factor: 4.507
Authors: Puneet Misra; Shashi Kant; Anoop Misra; Shreya Jha; Priyanka Kardam; Nishakar Thakur; Surya P Bhatt Journal: J Family Med Prim Care Date: 2021-08-27
Authors: Magdalena Basińska-Lewandowska; Andrzej Lewiński; Krzysztof C Lewandowski; Elżbieta Skowrońska-Jóźwiak Journal: Front Endocrinol (Lausanne) Date: 2022-09-14 Impact factor: 6.055